Calcium Release from Sarcoplasmic Reticulum Is Facilitated in Human Myotubes Derived from Carriers of the Ryanodine Receptor Type 1 Mutations Ile2182Phe and Gly2375Ala

Genetic Testing

Volumn 7, Issue 3, 2003, Pages 203-211

  Wehner, Markus ^a   Rueffert, H ^a   Koenig, F ^a   Olthoff, D ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CAFFEINE; CALCIUM ION; CHLOROCRESOL; FURA 2 ACETOXYMETHYL ESTER; GENOMIC DNA; GLYCINE; HALOTHANE; INHALATION ANESTHETIC AGENT; ISOLEUCINE; NEUROMUSCULAR DEPOLARIZING AGENT; PHENYLALANINE; RYANODINE RECEPTOR;

AMINO ACID SUBSTITUTION; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA SEQUENCE; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MALIGNANT HYPERTHERMIA; MOLECULAR GENETICS; MUSCLE BIOPSY; MUSCLE CONTRACTURE; MYOTUBE; POINT MUTATION; POLYMERASE CHAIN REACTION; QUADRICEPS FEMORIS MUSCLE; RYR1 GENE; SARCOPLASMIC RETICULUM;

ADULT; AGED; CAFFEINE; CALCIUM; CHILD; CHILD, PRESCHOOL; CRESOLS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HALOTHANE; HETEROZYGOTE; HUMANS; MALE; MALIGNANT HYPERTHERMIA; MIDDLE AGED; MUSCLE CONTRACTION; MUSCLE FIBERS; POINT MUTATION; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM;

EID: 0242330178     PISSN: 10906576     EISSN: None     Source Type: Journal    
DOI: 10.1089/109065703322537214     Document Type: Article

References (35)

1. BAUR, C.P., BELLON, L., FELLEITER, P. et al. (2000). A multicenter study of 4-chloro-m-cresol for diagnosing malignant hyperthermia susceptibility. Anesth. Analg. 90, 200-205.
2. BERRIDGE, M.J. (1997). Elementary and global aspects of calcium signalling. J. Exp. Biol. 200, 315-319.
3. BRINKMEIER, H., KRÄMER, J., KRÄMER, R., et al. (1999). Malignant hyperthermia causing Gly2435Arg mutation of the ryanodine receptor facilitates ryanodine-induced calcium release in myotubes. Br. J. Anaesth. 83, 855-861.
4. CENSIER, K., URWYLER, A., ZORZATO, F., et al. (1998). Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. J. Clin. Invest. 101, 1233-1242.
5. DIETZE, B., BERTOCCHINI, F., BARONE, V., et al. (1998). Voltage-controlled Ca2+ release in normal and ryanodine receptor type 3 (RyR3)-deficient mouse myotubes. J. Physiol. (Lond.) 513, 3-9.
6. EDOM-VOVARD, E., MOULY, V., BARBET, J.P., et al. (1999). The four populations of myoblasts involved in human limb muscle formation are present from onset of primary myotube formation. J. Cell Sci. 112, 191-199.
7. FAGERLUNG, T.H., ØRDING, H., BENDIXEN, D., et al. (1997). Discordance between malignant hyperthermia susceptibility and RYR1 mutation C1840T in two Scandinavian MH families exhibiting this mutatino. Clin. Genet. 52, 416-421.
8. FLUCHER, B.E., ANDREWS, S.B., FLEISCHER, S., et al. (1993). Triad formation: organization and function of the sarcoplasmic reticulum calcium release channel and triadin in normal and dysgenic muscle in vitro. J. Cell. Biol. 123, 1161-1174.
9. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260, 3440-3450.
10. HERMANN-FRANK, A., RICHTER, M., and LEHMANN-HORN, F. (1996). 4-Chloro-m-cersol: a specific tool to distinguish between malignant hyperthermia-susceptible and normal muscle. Biochem. Pharmacol. 52, 149-155.
11. ISAACS, H., and BADENHORST, M. (1993). False-negative results with muscle caffeine halothane contracture testing for malignant hyperthermia. Anesthesiology 79, 5-9.
12. JURKATT-ROTT, K., MCCARTHY, T., and LEHMANN-HORN, F. (2000). Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 23, 4-17.
13. LOPEZ, J.R., ALAMO, L., CAPUTO, C., et al. (1985). Intracellular ionized calcium concentration in muscles from humans with malignant hyperthermia. Muscle Nerve 8, 355-358.
14. LOPEZ, J.R., GERARDI, A., LOPEZ, M.J., et al. (1992). Effects of dantrolene on myoplasmic free [Ca2+] measured in vivo in patients susceptible to malignant hyperthermia. Anesthesiology 76, 711-719.
15. 2+ release channel function and severe central core disease. Proc. Natl. Acad. Sci. USA 96, 4164-4169.
16. MACLENNAN, D.H. (1995). Discordance between phenotype and genotype in malignant hyperthermia. Curr. Opin. Neurol. 8, 397-401.
17. MACLENNAN, D.H., DUFF, C., ZORZATO, F., et al. (1990). The ryanodine receptor gene: A candidate gene for preposition to malignant hyperthermia. Nature 343, 559-561.
18. MCCARTHY, T.V., HEALY, J.M.S., HEFFRON, J.J.A., et al. (1990). Localization of malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 343, 562-564.
19. MCCARTHY, T.V., QUANE, K.A., and LYNCH, P.J. (2000). Ryanodine receptor mutation in malignant hyperthermia and central core disease. Hum. Mutat. 15, 410-417.
20. O'SULLIVAN, G.H., MCINTOSH, J.M., and HEFFRON, J.J.A. (2001). Abnormal uptake and release of Ca2+ ions from human malignant hyperthermia-susceptible sarcoplasmic reticulum. Biochem. Pharmacol. 61, 1479-1485.
21. ØRDING, H., FOR THE EUROPEAN MALIGNANT HYPERTHERMIA GROUP. (1997). In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol. Scand. 41, 955-966.
22. RUEFFERT, H., KRAUS, H., OLTHOFF, D., et al. (2001). Identification of a novel mutation in the ryanodine receptor gene (RyR1) in patients with malignant hyperthermia. Hum. Murat. 17, 238.
23. SAMBUUGHIN, N., NELSON, T.E., JANKVIC, J., et al. (2001). Identification and functional characterization of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families. Neuromusc. Disord. 11, 530-537.
24. THE EUROPEAN MALIGNANT HYPERPYREXIA GROUP. (1984). A protocol for the investigation of Malignant hyperpyrexia (MH) susceptibility. Br. J. Anaesth. 56, 1267-1269.
25. TONG, J., OYAMADA, H., DEMAUREX, N., et al. (1997). Caffeine and halothane sensitivity of intracellular Ca:+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. Biochemistry 272, 26332-26339.
26. 2+ release channels. J. Biol. Chem. 274, 693-702.
27. 2+ transients in COS-7 cells transfected with the cDNA encoding skeletal-muscle ryanodine receptor carrying a mutation with malignant hyperthermia. Biochem. J. 301, 661-665.
28. URWYLER, A., DEUFEL, T., MCCARTHY, T., et al. FOR THE EUROPEAN MALIGNANT HYPERTHERMIA GROUP. (2001). Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br. J. Anaesth. 86, 283-287.
29. 2+ concentrations. Cell Calcium 12, 29-37.
30. +. Eur. J. Anaesth. 19(Suppl. 24), 114-115.
31. WEHNER, M., RUEFFERT, H., KOENIG, F., et al. (2002). Increased sensitivity to 4-chloro-m-cresol and caffeine in primary myotubes from MHS-individuals carrying the RyR1 Thr2206Met (C6617T) mutation. Clin. Genet. 62, 135-146.
32. WEISS, J.N. (1997). The Hill equation revisited: uses and misuses. FASEB J. 11, 835-841.
33. ZHANG, X.H., WU, J., SHEN, M.X., et al. (1999). Calcium release induced by high K+ and caffeine in cultuerd skeletal muscle cells of embryonic chicken. Pflügers Arch.-Eur. J. Physiol. 438, 827-836.
34. 2+ release. Mol. Pharmacol. 44, 1192-1201.
35. 2+ channel/ryanodine receptor: modulation by endogenous effectors, drugs and disease states. Pharmacol. Rev. 49, 1-51.